🔗 Share this article

Government ministers and leading parliamentarians have issued warnings that the United Kingdom's series of deals with Washington are "fundamentally unstable." This stems from revelations that a recently announced deal on drug pricing, which commits to zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond vague headline terms outlined by government press releases.

Lacking Legal Footing

The deal on drug tariffs, hailed as a "landmark" achievement, remains an "statement of intent" without a signed legal text. Critics have noted that the public statements from the UK and US governments describe the deal in markedly contrasting terms. The British version celebrates securing "zero per cent tariffs" as a singular success, while the American announcement concentrates on the expectation for the NHS to pay higher prices for new medications.

"We face a genuine possibility that the UK government has promised concessions to raise drug prices in return for little more than a pledge from President Trump," commented David Henig, a trade expert. "We know he has a record of not following through on agreements."

A Pattern of Unreliability

Anxieties have been amplified by Washington's action to put on ice the high-value digital accord, which was previously heralded as "a transformative pact" in the bilateral relationship. The US pointed to a insufficient movement from the UK on addressing wider trade issues as the reason for the pause.

Additionally, concessions secured for British farmers as part of an earlier tariff deal have not been formally approved by the US, despite a fast-approaching January deadline. "Our understanding is that the US has not yet signed off the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Behind the scenes, ministers have voiced worries that the government's US-UK accords are lacking substance. One minister described the series of agreements as "built on sand," while another framed the situation as the "prevailing condition" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, remarked: "The only thing more surprising than the US approach is the UK government's naive belief that his administration is a trustworthy negotiator. The NHS is too precious to be gambled with."

Government Downplays Risks, Points to Gains

Officials have attempted to minimize the risk of the US withdrawing from the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, wanting clarity on imports and pricing, making it less abstract than the paused tech deal.

Officials acknowledge that unpredictability is a feature of dealing with the Trump administration. However, they maintain that the UK has obtained tangible results for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a solid gain," one official said.

Nevertheless, delays have emerged in enacting the broader trade deal. Promised access for British beef have not materialized, and the assurance to "remove tariffs on British steel and aluminium" has is still pending, with tariffs staying at 25%.

Looking ahead, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.